R Looney

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
  2. ncbi B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis
    R J Looney
    University of Rochester, 601 Elmwood Avenue, Rm G 6454, Rochester, NY 14642, USA
    Rheumatology (Oxford) 44:ii13-ii17. 2005
  3. ncbi Use of intravenous immunoglobulin G (IVIG)
    R John Looney
    Department of Medicine, Allergy, Immunology, Rheumatology Unit, School of Medicine and Dentistry, University of Rochester, 595 Elmwood Ave, Room G 6454, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 19:3-25. 2006
  4. ncbi New therapies for systemic lupus erythematosus: cellular targets
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
    Rheum Dis Clin North Am 32:201-15, xi. 2006
  5. ncbi B cell-targeted therapy for rheumatoid arthritis: an update on the evidence
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Drugs 66:625-39. 2006
  6. ncbi Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases
    R John Looney
    Autoimmunity Centers of Excellence ACE Immunocompetency Committee, Rochester, USA
    Clin Immunol 123:235-43. 2007
  7. ncbi The effects of rituximab on immunocompetency in patients with autoimmune disease
    R John Looney
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 58:5-14. 2008
  8. ncbi A perspective on B-cell-targeting therapy for SLE
    R John Looney
    Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G 6427C, Rochester, NY, 14642, USA
    Mod Rheumatol 20:1-10. 2010
  9. ncbi B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Drugs 70:529-40. 2010
  10. ncbi B cell-targeted therapy in diseases other than rheumatoid arthritis
    R John Looney
    Allergy Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol Suppl 73:25-8; discussion 29-30. 2005

Research Grants

  1. Clinical Trials of New Therapy for Autoimmune Diseases
    R Looney; Fiscal Year: 2003
  2. ACETABULAR BONE LOSS AFTER PROSTHETIC HIP ARTHROPLASTY
    R Looney; Fiscal Year: 2005

Collaborators

Detail Information

Publications22

  1. ncbi Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
    ..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy...
  2. ncbi B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis
    R J Looney
    University of Rochester, 601 Elmwood Avenue, Rm G 6454, Rochester, NY 14642, USA
    Rheumatology (Oxford) 44:ii13-ii17. 2005
    ..However, early observations suggest that this approach is likely to yield significant clinical benefits in a wide range of organ-specific and systemic autoimmune diseases...
  3. ncbi Use of intravenous immunoglobulin G (IVIG)
    R John Looney
    Department of Medicine, Allergy, Immunology, Rheumatology Unit, School of Medicine and Dentistry, University of Rochester, 595 Elmwood Ave, Room G 6454, Rochester, NY 14642, USA
    Best Pract Res Clin Haematol 19:3-25. 2006
    ....
  4. ncbi New therapies for systemic lupus erythematosus: cellular targets
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
    Rheum Dis Clin North Am 32:201-15, xi. 2006
    ..This article discusses the B-cell abnormalities found in systemic lupus erythematosus and the clinical and immunologic effects of anti-B-cell therapies...
  5. ncbi B cell-targeted therapy for rheumatoid arthritis: an update on the evidence
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Drugs 66:625-39. 2006
    ..Thus, therapies specifically targeting B cells do appear to be effective in the treatment of RA, providing direct evidence that B cells are important in the pathogenesis of RA...
  6. ncbi Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases
    R John Looney
    Autoimmunity Centers of Excellence ACE Immunocompetency Committee, Rochester, USA
    Clin Immunol 123:235-43. 2007
    ..Banking genetic material to allow genotyping should be considered particularly if a central repository for samples from different trials can be established...
  7. ncbi The effects of rituximab on immunocompetency in patients with autoimmune disease
    R John Looney
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 58:5-14. 2008
  8. ncbi A perspective on B-cell-targeting therapy for SLE
    R John Looney
    Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G 6427C, Rochester, NY, 14642, USA
    Mod Rheumatol 20:1-10. 2010
    ....
  9. ncbi B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Drugs 70:529-40. 2010
    ..Thus, recent clinical trial data show that B cell-targeting therapies are beginning to fulfil their promise as treatments for SLE and there are good reasons to hope for further progress in the near future...
  10. ncbi B cell-targeted therapy in diseases other than rheumatoid arthritis
    R John Looney
    Allergy Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol Suppl 73:25-8; discussion 29-30. 2005
    ..Based on these reports, further controlled studies are warranted to optimize RTX as monotherapy and to develop combination therapies in patients with refractory autoimmune diseases...
  11. ncbi Treating human autoimmune disease by depleting B cells
    R J Looney
    University of Rochester, Rochester, New York 14642, USA
    Ann Rheum Dis 61:863-6. 2002
  12. ncbi Treatment of SLE with anti-CD20 monoclonal antibody
    R John Looney
    Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Curr Dir Autoimmun 8:193-205. 2005
    ..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)...
  13. ncbi B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 50:2580-9. 2004
    ..B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE...
  14. ncbi B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells
    R J Looney
    Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Lupus 13:381-90. 2004
    ..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)...
  15. ncbi B cells as therapeutic targets for rheumatic diseases
    R John Looney
    Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Curr Opin Rheumatol 16:180-5. 2004
    ....
  16. ncbi Effect of aging on cytokine production in response to respiratory syncytial virus infection
    Richard J Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Infect Dis 185:682-5. 2002
    ..This defect in cellular immunity may be related to the increased morbidity observed with RSV infection in elderly persons...
  17. ncbi Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear
    R John Looney
    Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res 4:59-63. 2002
    ....
  18. ncbi Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis
    E M Schwarz
    Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res 2:165-8. 2000
    ..Here we review recent studies implicating tumor necrosis factor (TNF)-alpha in periprosthetic osteolysis and the rationale for clinical studies of anti-TNF therapy and other interventions for periprosthetic loosening...
  19. ncbi RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis
    C T Ritchlin
    The Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester 14642, USA
    J Musculoskelet Neuronal Interact 4:276-84. 2004
    ..Herein, we provide a review of the role of RANK, RANKL and OPG in erosive arthritis and periprosthetic osteolysis and discuss the potential of anti-RANKL therapy for these conditions...
  20. ncbi Bone implant interface, osteolysis and potential therapies
    E M Schwarz
    The Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Musculoskelet Neuronal Interact 4:390-2. 2004
  21. ncbi Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loosening of total joint components
    P F Pollice
    Department of Orthopaedics, University of Rochester Medical Center, New York 14642, USA
    J Bone Joint Surg Am 83:1057-61. 2001
    ..This effect could increase implant longevity and decrease the need for revision arthroplasty...
  22. ncbi Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults
    A R Falsey
    Department of Medicine, Rochester General Hospital, Rochester, New York 14621, USA
    J Med Virol 59:221-6. 1999
    ..These data suggest that the severe clinical manifestations of RSV in the elderly are not due to a significant defect in humoral immunity...

Research Grants5

  1. Clinical Trials of New Therapy for Autoimmune Diseases
    R Looney; Fiscal Year: 2003
    ..abstract_text> ..
  2. ACETABULAR BONE LOSS AFTER PROSTHETIC HIP ARTHROPLASTY
    R Looney; Fiscal Year: 2005
    ..In addition, DNA and serum samples from all subjects studied in this proposal will be banked. ..